[Ovarian cancers and CA 125 in 2006].
The authors propose to report progress on the use of the CA 125 serum assay. It affects three situations: screening, diagnosis and the follow-up of the patients dealt with ovarian tumour either of benign or malignant nature. For each situation the interest and the relevance of CA 125 assay will be approached.
Lambaudie
E
E
Service de gynécologie chirurgicale, hôpital Jeanne-de-Flandre, CHRU de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France. e-lambaudie@chru-lille.fr
Collinet
P
P
Vinatier
D
D
D014408:Biomarkers, Tumor / Q000032:analysis / Q000276:immunology; D018394:CA-125 Antigen / Q000032:analysis* / Q000276:immunology; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008593:Menopause; D010049:Ovarian Diseases / Q000175:diagnosis* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000473:pathology; D018570:Risk Assessment
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen